K-pop

EXO’s Sehun Releases New Chinese Song “Fade”… Featuring NCT WISH’s Sion

R&B Pop Track Themed “A World Without Gravity” As part of Warner Music China’s music streaming project

KIM HYUNSIK
2026-07-29 14:04:50
[Edaily Starin KIM HYUNSIK Reporter] EXO member Sehun released his new Chinese-language song “Fade” at 12:00 p.m. on the 29th via various online music platforms.
EXO’s Sehun (Photo: Warner Music)
“Fade” is an emotional R&B pop track centered on the theme of a world that has lost its gravity. NCT WISH member Sion participated in the song as a featured artist.
SM Entertainment (SM), the agency representing both artists, stated, “Sehun and Sion showcased the chemistry of an ‘SM senior-junior’ collaboration through their melodious vocals.”
“Fade” was also produced as part of a collaborative music project currently underway with Warner Music China. SM explained, “The project came about after Warner Music China proposed that Sehun participate as a vocalist.”
Meanwhile, EXO, the group to which Sehun belongs, recently concluded their solo concert tour “EXO PLANET #6 – EXhOrizon,” which consisted of 27 shows across 14 regions worldwide.

Economy

Corporation

IT·Science

Economy

SamsungElectronics Has 7.97 Million Minority Shareholders—a Record High… Up by 2.81 Million in a Year and a Half

The number of SamsungElectronics’ small shareholders has increased by more than 2.81 million in a year and a half, approaching 8 million. This means that more than half of domestic retail investors ho…
2026-11-10 09:10:29

Corporation

CJ CheilJedang Corp Reports Third-Quarter Operating Profit of 309 billion won… Down 10.8% Year-Over-Year (First Report)

CJ CheilJedang Corp(097950)announced on the 10th that its consolidated operating profit for the third quarter of this year was provisionally estimated at 309 billion won, a 10.8% decrease compared to …
2026-11-10 09:36:38

IT·Science

MedPacto, Inc.’s ‘MP010’ Shows Tumor Disappearance Rates of Up to 87.5% in Preclinical Pancreatic Cancer Studies… Published in ‘Cancer Cell’

MedPacto, Inc.(235980)’s next-generation anticancer drug candidate “MP010” has demonstrated tumor regression and long-term immune memory effects in a pancreatic cancer animal model. MedPacto, Inc. …
2026-11-10 09:46:02